The pharmaceutical company's MariTide treatment performed well in a Phase 2 study but not as well as Wall Street expected.

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

Amgen said its experimental weight loss injection helped patients lose up to 20% of their weight on average after a year, ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might ...

An Amgen obesity drug helped participants lose a substantial amount of weight, but questions about how competitive it could ...

Amgen's latest once-monthly weight loss drug data looks "OK," analysts say, as its path to approval still remains murky.

Amgen (AMGN) stock slips as company posts mid-stage trial data for weight loss therapy MariTide. Rivals Eli Lilly (LLY) and ...

The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...

Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...